Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas
A Trabolsi, A Arumov, JH Schatz - Blood Cancer Journal, 2024 - nature.com
Despite recent advances in frontline therapy for diffuse large B-cell lymphoma (DLBCL), at
least a third of those diagnosed still will require second or further lines for relapsed or …
least a third of those diagnosed still will require second or further lines for relapsed or …